Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594707 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT04594707 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 117 participants.
The verdict
NCT04594707, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG PRM-151 (Zinpentraxin Alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04594707
The ClinicalTrials.gov registry entry for NCT04594707 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRM-151 (Zinpentraxin Alfa) is the first listed.
NCT04594707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04594707 about?
NCT04594707 is a clinical study titled "A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis". This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT04594707?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2021-08-30. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT04594707?
The interventions under investigation include: PRM-151 (Zinpentraxin Alfa) (DRUG).
Who is sponsoring clinical trial NCT04594707?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.